These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 33002893)

  • 1. Genomic Study of Chinese Quadruple-negative GISTs Using Next-generation Sequencing Technology.
    Wang S; Sun RZ; Han Q; Wang SY; Wang EH; Liu Y
    Appl Immunohistochem Mol Morphol; 2021 Jan; 29(1):34-41. PubMed ID: 33002893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quadruple-Negative GIST Is a Sentinel for Unrecognized Neurofibromatosis Type 1 Syndrome.
    Gasparotto D; Rossi S; Polano M; Tamborini E; Lorenzetto E; Sbaraglia M; Mondello A; Massani M; Lamon S; Bracci R; Mandolesi A; Frate E; Stanzial F; Agaj J; Mazzoleni G; Pilotti S; Gronchi A; Dei Tos AP; Maestro R
    Clin Cancer Res; 2017 Jan; 23(1):273-282. PubMed ID: 27390349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gastrointestinal stromal tumors - Summary of mutational status of the primary/secondary KIT/PDGFRA mutations, BRAF mutations and SDH defects.
    Kalfusova A; Linke Z; Kalinova M; Krskova L; Hilska I; Szabova J; Vicha A; Kodet R
    Pathol Res Pract; 2019 Dec; 215(12):152708. PubMed ID: 31708372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene duplication, rather than epigenetic changes, drives FGF4 overexpression in KIT/PDGFRA/SDH/RAS-P WT GIST.
    Urbini M; Astolfi A; Indio V; Nannini M; Schipani A; Bacalini MG; Angelini S; Ravegnini G; Calice G; Del Gaudio M; Secchiero P; Ulivi P; Gruppioni E; Pantaleo MA
    Sci Rep; 2020 Nov; 10(1):19829. PubMed ID: 33199729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identifying Secondary Mutations in Chinese Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs) by Next Generation Sequencing (NGS).
    Du J; Wang S; Wang R; Wang SY; Han Q; Xu HT; Yang P; Liu Y
    Pathol Oncol Res; 2020 Jan; 26(1):91-100. PubMed ID: 31758409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological and molecular features of a large cohort of gastrointestinal stromal tumors (GISTs) and review of the literature: BRAF mutations in KIT/PDGFRA wild-type GISTs are rare events.
    Huss S; Pasternack H; Ihle MA; Merkelbach-Bruse S; Heitkötter B; Hartmann W; Trautmann M; Gevensleben H; Büttner R; Schildhaus HU; Wardelmann E
    Hum Pathol; 2017 Apr; 62():206-214. PubMed ID: 28159677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular and clinicopathological features of KIT/PDGFRA wild-type gastrointestinal stromal tumors.
    Nishida T; Naito Y; Takahashi T; Saito T; Hisamori S; Manaka D; Ogawa K; Hirota S; Ichikawa H
    Cancer Sci; 2024 Mar; 115(3):894-904. PubMed ID: 38178783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical loss of succinate dehydrogenase subunit A (SDHA) in gastrointestinal stromal tumors (GISTs) signals SDHA germline mutation.
    Miettinen M; Killian JK; Wang ZF; Lasota J; Lau C; Jones L; Walker R; Pineda M; Zhu YJ; Kim SY; Helman L; Meltzer P
    Am J Surg Pathol; 2013 Feb; 37(2):234-40. PubMed ID: 23282968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intratumoral KIT mutational heterogeneity and recurrent KIT/ PDGFRA mutations in KIT/PDGFRA wild-type gastrointestinal stromal tumors.
    Gao J; Li J; Li Y; Li Z; Gong J; Wu J; Liu N; Dong B; Qi C; Li J; Shen L
    Oncotarget; 2016 May; 7(21):30241-9. PubMed ID: 26848617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcriptome sequencing identifies ETV6-NTRK3 as a gene fusion involved in GIST.
    Brenca M; Rossi S; Polano M; Gasparotto D; Zanatta L; Racanelli D; Valori L; Lamon S; Dei Tos AP; Maestro R
    J Pathol; 2016 Mar; 238(4):543-9. PubMed ID: 26606880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAF mutations in KIT/PDGFRA positive gastrointestinal stromal tumours (GISTs): Is their frequency underestimated?
    Jašek K; Váňová B; Grendár M; Štanclová A; Szépe P; Hornáková A; Holubeková V; Plank L; Lasabová Z
    Pathol Res Pract; 2020 Nov; 216(11):153171. PubMed ID: 32836055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrated genomic study of quadruple-WT GIST (KIT/PDGFRA/SDH/RAS pathway wild-type GIST).
    Nannini M; Astolfi A; Urbini M; Indio V; Santini D; Heinrich MC; Corless CL; Ceccarelli C; Saponara M; Mandrioli A; Lolli C; Ercolani G; Brandi G; Biasco G; Pantaleo MA
    BMC Cancer; 2014 Sep; 14():685. PubMed ID: 25239601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preferential MGMT methylation could predispose a subset of KIT/PDGFRA-WT GISTs, including SDH-deficient ones, to respond to alkylating agents.
    Ricci R; Martini M; Ravegnini G; Cenci T; Milione M; Lanza P; Pierconti F; Santini D; Angelini S; Biondi A; Rosa F; Alfieri S; Clemente G; Persiani R; Cassano A; Pantaleo MA; Larocca LM
    Clin Epigenetics; 2019 Jan; 11(1):2. PubMed ID: 30616628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quadruple wild-type (WT) GIST: defining the subset of GIST that lacks abnormalities of KIT, PDGFRA, SDH, or RAS signaling pathways.
    Pantaleo MA; Nannini M; Corless CL; Heinrich MC
    Cancer Med; 2015 Jan; 4(1):101-3. PubMed ID: 25165019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel oncogene and tumor suppressor mutations in KIT and PDGFRA wild type gastrointestinal stromal tumors revealed by next generation sequencing.
    Hechtman JF; Zehir A; Mitchell T; Borsu L; Singer S; Tap W; Oultache A; Ladanyi M; Nafa K
    Genes Chromosomes Cancer; 2015 Mar; 54(3):177-84. PubMed ID: 25427437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Molecular mechanisms of primary and secondary resistance, molecular-genetic features and characteristics of KIT/PDGFRA non-mutated GISTs].
    Kalfusová A; Kodet R
    Cesk Patol; 2017; 53(4):167-173. PubMed ID: 29227120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of mutations in the BRAF gene in patients with KIT and PDGFRA wild-type gastrointestinal stromal tumors.
    Jasek K; Buzalkova V; Minarik G; Stanclova A; Szepe P; Plank L; Lasabova Z
    Virchows Arch; 2017 Jan; 470(1):29-36. PubMed ID: 27864688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours.
    Agaimy A; Terracciano LM; Dirnhofer S; Tornillo L; Foerster A; Hartmann A; Bihl MP
    J Clin Pathol; 2009 Jul; 62(7):613-6. PubMed ID: 19561230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low frequency of MAP kinase pathway alterations in KIT and PDGFRA wild-type GISTs.
    Martinho O; Gouveia A; Viana-Pereira M; Silva P; Pimenta A; Reis RM; Lopes JM
    Histopathology; 2009 Jul; 55(1):53-62. PubMed ID: 19614767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic.
    Boikos SA; Pappo AS; Killian JK; LaQuaglia MP; Weldon CB; George S; Trent JC; von Mehren M; Wright JA; Schiffman JD; Raygada M; Pacak K; Meltzer PS; Miettinen MM; Stratakis C; Janeway KA; Helman LJ
    JAMA Oncol; 2016 Jul; 2(7):922-8. PubMed ID: 27011036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.